Ensysce Biosciences Submits Phase 3 Protocol to the FDA

September 19, 2024 7:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has submitted to the FDA its PF614-301 protocol of the study, "A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of...

Read more

Faro Health Joins Veeva Product Partner Program

September 18, 2024 7:00 AM

Partnership enables an integration to improve the productivity of clinical development team.SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Faro Health Inc., the leading AI-powered platform for clinical protocol design, today announced it joined the Veeva Product Partner Program. With this partnership, Faro Health will develop an integration between Faro's Study Designer and Veeva Vault EDC.Faro Health offers tools and insights for...

Read more

Vicore Publishes Prospectus Relating to the Rights Issue

September 18, 2024 6:00 AM

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.STOCKHOLM, SE / ACCESSWIRE / September 18, 2024 / Vicore Pharma Holding...

Read more

XiltriX North America Achieves ISO 9001:2015 Recertification, Demonstrating Commitment to Continuous Quality Improvement

September 17, 2024 9:07 AM

SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / XiltriX North America is the only real-time environmental monitoring provider in the life science industry that holds ISO 9001:2015 recertification for Quality Management Systems (QMS) and a SOC 2 Type 2 attestation. This recertification highlights XiltriX's ongoing commitment to maintaining the highest standards of quality and continuous improvement in its service offerings. "We are thrilled...

Read more

New Immuno-Oncology Research Team in Partnership with Ono Pharmaceutical Starts at BioMed X Institute

September 17, 2024 6:30 AM

BioMed X, a German biomedical research institute, announced the start of a new research team at the BioMed X Institute in Heidelberg, Germany, the institute's first joint research project with the Japanese company Ono Pharmaceutical Co., Ltd. The scope of this project is to investigate the antitumor effects of neutrophils to develop novel next-generation immunotherapies. Ono Pharmaceutical and BioMed X Institute launch new collaboration in...

Read more

Announcement from Biovica International AB's Annual General Meeting

September 17, 2024 5:20 AM

UPPSALA, SE / ACCESSWIRE / September 17, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 17 September 2024 and the following resolutions were passed by the meeting.ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEETThe annual general meeting resolved to adopt Biovica's income statement and balance sheet as well as the...

Read more

Biovica Signs Agreement with Clinical-Stage US Biotech Company

September 17, 2024 2:50 AM

UPPSALA, SE / ACCESSWIRE / September 17, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) with a US-based biotech company focusing on next generation CDK inhibitors.Under the agreement, Biovica will provide TKa testing services utilizing Biovica's DiviTum® TKa assay and expertise in interpreting TKa measurement dynamics to support drug...

Read more

Vicore Announces Additional Subscription Undertaking from HealthCap

September 17, 2024 2:20 AM

STOCKHOLM, SE / ACCESSWIRE / September 17, 2024 / Vicore Pharma Holding (STO:VICO)THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS...

Read more

ONI Expands Horizons: Entering the Lipid Nanoparticle Research Market

September 16, 2024 9:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 16, 2024 / ONI, a leader in super-resolution microscopy technology, is excited to announce its strategic entry into the lipid nanoparticle (LNP) research sector. This move showcases ONI's commitment to driving innovation in therapeutic delivery systems crucial for mRNA vaccines, gene therapies, and personalized medicine. Lipid nanoparticles represent a groundbreaking approach to encapsulating and...

Read more

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

September 16, 2024 8:20 AM

Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor TypesProlonged stable disease lasting >11 months demonstrated in Breast Cancer PatientFavorable Pharmacokinetics, Safety and Tolerability ObservedData Presented at the European Society of Medical Oncology on September 14, 2024LUND, SE / ACCESSWIRE / September 16, 2024 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm:ATORX) and AptevoTherapeutics ("Aptevo")...

Read more

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

September 16, 2024 7:00 AM

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody,...

Read more

BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments

September 14, 2024 6:00 AM

LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV)Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to modulate the tumor microenvironment, turning a "cold" tumor to "hot", enhancing the potential of T cell infiltration and a shift to PD(L)-1...

Read more

Moolec Received NASDAQ Bid Price Letter

September 13, 2024 6:30 PM

LUXEMBOURG / ACCESSWIRE / September 13, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today that it received a letter (the "Nasdaq Bid Price Letter") from Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's ordinary shares has been below the minimum $1.00 per share required for continued listing on The Nasdaq...

Read more

Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024

September 13, 2024 8:20 AM

LUND, SE / ACCESSWIRE / September 13, 2024 / Alligator Bioscience AB ("Alligator") (Nasdaq Stockholm:ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO) today announced that positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Saturday, September 14, 2024, at the European Society for Medical Oncology (ESMO) Annual Congress 2024, taking place September 13th...

Read more

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

September 13, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, has made available two video segments from its August 8th symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam,...

Read more

Correction: Q1 Interim Report May-July 2024/2025

September 12, 2024 4:50 AM

Correction due to missing MAR-legendUPPSALA, SE / ACCESSWIRE / September 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Significantly increased sales in the USA and much improved cash flowSEK tQ1 24/25Q1 23/24May-April 23/24Net sales1,7141,7667,290Operating profit (loss)-23,562-32,192-126,845Earnings per share after dilution-0.27-0.70-2.14Number of shares at the end of the period*84,055,56045,741,39484,055,560Cash and...

Read more

BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma

September 12, 2024 2:50 AM

First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024Clinical supply agreement for acalabrutinib with AstraZeneca in placeLUND, SE / ACCESSWIRE / September 12, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy,...

Read more

Q1 Interim Report May-July 2024/2025

September 12, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / September 12, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Significantly increased sales in the USA and much improved cash flowSEK tQ1 24/25Q1 23/24May-April 23/24Net sales1,7141,7667,290Operating profit (loss)-23,562-32,192-126,845Earnings per share after dilution-0.27-0.70-2.14Number of shares at the end of the period*84,055,56045,741,39484,055,560Cash and cash equivalents at the end of the...

Read more

Tesla BioHealing and Cell Biotechnology Co., Ltd. Forge Strategic Partnership to Transform Stem Cell Therapies

September 11, 2024 8:00 PM

BUTLER, PA / ACCESSWIRE / September 11, 2024 / Tesla BioHealing-PA, LLC, a leader in biophoton life force technology, and Cell Biotechnology Co., Ltd, an innovator in stem cell transplantation, have entered a strategic collaboration to revolutionize the development and delivery of stem cell therapies. This partnership, effective September 9, 2024, unites the companies' groundbreaking technologies to significantly enhance patient outcomes by...

Read more

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

September 11, 2024 9:15 AM

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussionsNEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial study to determine consumer comprehension of the...

Read more